News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ludwig Institute For Cancer Research (LICR) and Pro-Pharmaceuticals, Inc. (PRW) Discover That DAVANAT(R) Enhances the Ability of Anti-Tumor T Lymphocytes to Kill Tumor Cells


4/20/2011 8:45:23 AM

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTC:PRWP) today announced that the Brussels Branch of the Ludwig Institute for Cancer Research demonstrated the ability of GM-CT-01 (DAVANATĀ®) to enhance the ability of tumor-specific T-lymphocytes to kill tumor cells.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES